A Phase 2 interventional study of Tesamorelin and Placebo in Chronic Obstructive Pulmonary Disease (COPD), sponsored by Theratechnologies. Terminated. Open to participants aged 40 Years to 75 Years. Per ClinicalTrials.gov, last updated 2022-03-18.
Sponsored by Theratechnologies · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
A significant proportion of COPD subjects experience muscle wasting, which has been associated with increased morbidity, impaired physical functioning, and a poor quality of life.
Muscle wasting is associated with reduced muscle strength in COPD subjects. In particular, weakness of peripheral muscles has been reported to play an important role in the reduced functional capacity and impaired exercise performance.
The primary objective of this study is to investigate the effect of tesamorelin, in conjunction with exercise training, on lean body mass measured by dual energy x-ray absorptiometry (DXA) scan.
5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 856 are open to participants now.
This study's enrollment of 3 is below the median of 62 across 3,841 interventional studies indexed under Pulmonary Disease, Chronic Obstructive.
Browse Pulmonary Disease, Chronic Obstructive studies →Theratechnologies is the lead sponsor of 10 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Tesamorelin 2 mg/day
Drug: Tesamorelin
Tesamorelin 3 mg/day
Drug: Tesamorelin
Placebo
Drug: Placebo
Change From Baseline in Lean Body Mass at 6 Months
The primary objective of the study was to evaluate the effect of tesamorelin on lean body mass by Dual-energy X-ray absorptiometry (DXA) scan
Time frame: 6 months
Change From Baseline in Exercise Capacity at 6 Months
Time frame: 6 months
Change From Baseline in Peripheral Muscle Strength at 6 Months
Time frame: 6 months
Change From Baseline in Patient-reported Outcomes at 6 Months
Time frame: 6 months
Adverse Events
Number and percentage of subjects with adverse events
Time frame: 6 months
COPD Exacerbations
Frequency and severity of COPD exacerbations
Time frame: 6 months
Plasma Glucose
Changes from baseline in fasting blood glucose
Time frame: 6 months
| Milestone | Tesamorelin 2 mg | Tesamorelin 3 mg | Placebo |
|---|---|---|---|
| Started | 1 | 1 | 0 |
| Completed | 1 | 1 | 0 |
| Not completed | 0 | 0 | 0 |
The primary objective of the study was to evaluate the effect of tesamorelin on lean body mass by Dual-energy X-ray absorptiometry (DXA) scan
No measurements were reported for this outcome.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Number and percentage of subjects with adverse events
Results for this outcome have not been posted.
Frequency and severity of COPD exacerbations
Results for this outcome have not been posted.
Changes from baseline in fasting blood glucose
Results for this outcome have not been posted.
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Tesamorelin 2 mg | — | 0/1 (0%) | 0/1 (0%) |
| Tesamorelin 3 mg | — | 0/1 (0%) | 0/1 (0%) |
| Placebo | — | — | — |
| Age, Continuous(years) | Tesamorelin 2 mg | Tesamorelin 3 mg | Placebo | Total |
|---|---|---|---|---|
| Mean | 59 ± 0 | 51 ± 0 | — | 55 ± 0 |
| Sex: Female, Male(Participants) | Tesamorelin 2 mg | Tesamorelin 3 mg | Placebo | Total |
|---|---|---|---|---|
| Female | 0 | 1 | — | 1 |
| Male | 1 | 0 | — | 1 |
| Region of Enrollment(participants) | Tesamorelin 2 mg | Tesamorelin 3 mg | Placebo | Total |
|---|---|---|---|---|
| United States | 1 | 1 | — | 2 |
No study locations are listed for this record.
The record gives a start of Sep 2011, a primary completion of Dec 2011 and a completion of Dec 2011. It does not say whether these dates are actual or estimated.
Results were first posted in May 2014, 2 years 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tesamorelin
Pulmonary Disease, Chronic Obstructive →
Theratechnologies